1. Home
  2. FLYW vs CDNA Comparison

FLYW vs CDNA Comparison

Compare FLYW & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Flywire Corporation Voting

FLYW

Flywire Corporation Voting

HOLD

Current Price

$17.13

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo CareDx Inc.

CDNA

CareDx Inc.

HOLD

Current Price

$54.33

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLYW
CDNA
Founded
2009
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Medical Specialities
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.6B
IPO Year
2021
2007

Fundamental Metrics

Financial Performance
Metric
FLYW
CDNA
Price
$17.13
$54.33
Analyst Decision
Buy
Buy
Analyst Count
14
6
Target Price
$16.21
$28.00
AVG Volume (30 Days)
1.2M
1.0M
Earning Date
05-05-2026
04-28-2026
Dividend Yield
N/A
N/A
EPS Growth
450.00
N/A
EPS
0.03
2.13
Revenue
$623,025,000.00
$48,324,000.00
Revenue This Year
$19.68
$16.01
Revenue Next Year
$15.25
$11.31
P/E Ratio
$577.67
$25.21
Revenue Growth
26.59
18.93
52 Week Low
$10.55
$13.95
52 Week High
$19.73
$55.16

Technical Indicators

Market Signals
Indicator
FLYW
CDNA
Relative Strength Index (RSI) 39.85 68.92
Support Level $17.09 $45.74
Resistance Level $19.02 N/A
Average True Range (ATR) 0.62 2.02
MACD -0.16 -0.03
Stochastic Oscillator 15.61 81.33

Price Performance

Historical Comparison
FLYW
CDNA

About FLYW Flywire Corporation Voting

Flywire Corp provides a secure payment platform, offering its clients a streamlined process to receive reconciled domestic and international payments more cost-effectively and efficiently. The company's solutions are built on three core elements, namely a payments platform, a proprietary payment network, and vertical-specific software backed by its deep industry expertise. Geographically, the majority of revenue is from the Americas.

About CDNA CareDx Inc.

CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.

Share on Social Networks: